MCP 202

Drug Profile

MCP 202

Alternative Names: BIO302; DPI-221

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Mount Cook Biosciences
  • Developer Mt Cook Pharma
  • Class Antispasmodics
  • Mechanism of Action Opioid delta receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Urinary incontinence

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Urinary-incontinence(In volunteers) in USA (PO)
  • 08 Jun 2010 Phase-I clinical trials in Urinary incontinence in USA (PO)
  • 07 Jun 2005 Data presented at the 100th Annual Meeting of the American Urological Association (AUA-2005)have been added to the Genitourinary disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top